Daré Bioscience faces Nasdaq listing deficiency notice
Daré Bioscience, Inc. reports that Nasdaq’s Listing Qualifications Staff notified it on July 13, 2026 that its common stock no longer complies with Nasdaq Listing Rule 5550(b).
Rhea-AI Filing Summary
Daré Bioscience, Inc. reports that Nasdaq’s Listing Qualifications Staff notified it on July 13, 2026 that its common stock no longer complies with Nasdaq Listing Rule 5550(b). The company’s Form 10-Q for the period ended March 31, 2026 reported stockholders’ equity of less than $2.5 million, and as of that date it also did not meet alternative requirements of $35 million market value of listed securities or $500,000 in net income from continuing operations.
The company plans to timely request a hearing before a Nasdaq Hearing Panel, which will stay any suspension or delisting at least until the Panel issues its decision and any extension period expires. The company cautions there is no assurance an extension will be granted, that compliance will be regained within any extension, or that its common stock will remain listed on Nasdaq.
Positive
- None.
Negative
- Nasdaq listing deficiency notice states Daré Bioscience’s common stock is subject to delisting after equity fell below $2.5M and alternative $35M market value and $500K net income tests were not met.
8-K Event Classification
Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
1 item
Item 3.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Securities
The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.
Key Figures
Stockholders’ equity threshold: $2.5 million
Market value alternative test: $35 million
Net income alternative test: $500,000
+1 more
4 metrics
Stockholders’ equity threshold
$2.5 million
Equity reported in Form 10-Q for period ended March 31, 2026 was less than this amount, triggering non-compliance with Nasdaq Listing Rule 5550(b).
Market value alternative test
$35 million
Alternative Nasdaq Listing Rule 5550(b) requirement for market value of listed securities that was not met as of July 13, 2026.
Net income alternative test
$500,000
Alternative Nasdaq Listing Rule 5550(b) requirement for net income from continuing operations that was not met as of July 13, 2026.
Nasdaq notice date
July 13, 2026
Date Nasdaq Listing Qualifications Staff notified the company of non-compliance and potential delisting.
Key Terms
Nasdaq Listing Rule 5550(b), stockholders’ equity, market value of listed securities, net income from continuing operations, +1 more
5 terms
Nasdaq Listing Rule 5550(b) regulatory
"the Company no longer complies with Nasdaq Listing Rule 5550(b)"
A Nasdaq listing rule that requires companies on the Nasdaq Capital Market to keep their share price at or above a minimum level (commonly $1.00 per share) to avoid delisting. It matters to investors because dropping below that threshold can start a formal review that may remove a stock from the exchange, which can reduce trading liquidity, make shares harder to sell, and hurt a company’s ability to raise capital — similar to a store losing its grade and being forced to close or move to a less prominent location.
stockholders’ equity financial
"Form 10-Q for the period ended March 31, 2026 reported stockholders’ equity"
Stockholders’ equity is the portion of a company’s value that belongs to its owners after subtracting what the company owes from what it owns — like the equity in a house after paying the mortgage. For investors it shows the company’s net worth and can indicate financial strength, a cushion against losses, and the amount potentially available to support dividends or reinvestment; tracking changes helps assess whether the business is building or eroding owner value.
market value of listed securities financial
"did not meet the alternative requirements of $35 million in market value of listed securities"
Market value of listed securities is the market value of the shares a company has listed on an exchange, calculated as the closing bid price multiplied by the number of listed shares. Exchanges use it as a continued-listing standard, so a company that stays under the required minimum receives a deficiency notice and is given a set period to recover before facing delisting.
net income from continuing operations financial
"or $500,000 in net income from continuing operations"
Net income from continuing operations is the profit a company earns from its ongoing, day-to-day business after paying costs, interest and taxes, excluding results from businesses it has sold or closed and one-time gains or losses. Investors care because it shows the company's recurring earning power—like comparing a regular paycheck to a one-off bonus—and gives a clearer picture of sustainable profits used to value the business and judge management performance.
Nasdaq Hearing Panel regulatory
"request a hearing before a Nasdaq Hearing Panel"
A Nasdaq hearing panel is a group of independent reviewers who decide whether a publicly listed company has broken the exchange’s rules and what penalties, if any, should apply. Think of it like a neighborhood committee that reviews complaints and can impose fines, require fixes, or remove a member; for investors, the panel’s rulings can affect whether a stock keeps trading, faces suspension, or suffers reputational and price impact.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Why did Daré Bioscience (DARE) receive a Nasdaq delisting notice?
Nasdaq notified Daré Bioscience that it no longer complies with Listing Rule 5550(b) because its Form 10-Q reported stockholders’ equity below $2.5 million and, as of July 13, 2026, it also did not meet the $35 million market value or $500,000 net income alternatives.
What specific Nasdaq rule did Daré Bioscience (DARE) fail to meet?
Daré Bioscience was cited for non-compliance with Nasdaq Listing Rule 5550(b). This rule requires either at least $2.5 million stockholders’ equity, or $35 million market value of listed securities, or $500,000 net income from continuing operations over specified periods.
What action will Daré Bioscience (DARE) take in response to the Nasdaq notice?
Daré Bioscience intends to timely request a hearing before a Nasdaq Hearing Panel. That request will stay any suspension or delisting of its common stock at least until the Panel issues its decision and any granted extension period ends.
Does the Nasdaq notice mean Daré Bioscience (DARE) will definitely be delisted?
The notice states Daré Bioscience’s common stock is subject to delisting unless it requests a hearing. The company plans to seek a hearing, but it notes there is no assurance that an extension will be granted, that it will regain compliance, or that its Nasdaq listing will be maintained.
What financial thresholds under Rule 5550(b) apply to Daré Bioscience (DARE)?
Under Nasdaq Listing Rule 5550(b), Daré Bioscience must meet at least one of these: $2.5 million stockholders’ equity, or $35 million market value of listed securities, or $500,000 net income from continuing operations, as described in the rule’s continued listing standards.
AI-generated analysis. How Rhea-AI works. Not financial advice.
